younger postmenopausal women when the risk-factor profile raises concern
women who have a history of fracture
Postmenopausal women who have osteoporosis and are treated with once-yearly IV zoledronic acid have a higher risk of serious atrial fibrillation than nonusers do
Nononcology patients who are starting an oral or IV bisphosphonate do not require a dental examination beforehand, provided dental care is appropriate and oral hygiene is good
The average duration of alendronate use among patients who had this fracture pattern was 6.9 years, compared with 2.5 years among women who did not
Dr. Goldstein is Professor of Obstetrics and Gynecology at New York University School of Medicine in New York City. He is also Director of Gynecologic Ultrasound and Co-Director of Bone Densitometry at New York University Medical Center.
